Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc outlined an evolution of its operating model to support its “Win as One” strategy, aiming to drive growth, productivity and culture, with changes expected to be implemented by mid-2026. The company has created a new Chief Growth Officer role that will oversee Category, Marketing and Strategy functions, plus a new global Commercial Excellence team, and will lead the growth and innovation agenda together with R&D, Supply Chain and new Operating Units.
Haleon is also reorganising into six Operating Units, splitting the current EMEA & LatAm region into Latin America, Middle East and Africa, and Europe, and establishing India Subcontinent as its own unit separate from Asia Pacific, while North America remains unchanged. In addition, a new Chief Transformation Officer will coordinate transformation across business processes, the operating model and technology. The CGO, CTO and each Operating Unit President will join the Executive Committee and report to CEO Brian McNamara. Further detail is expected with the Preliminary Full Year Results scheduled for 25 February 2026.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. The company disclosed that on 5 January 2026, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers, both classified as persons discharging managerial responsibilities (PDMRs), acquired ordinary shares in Haleon.
Each PDMR acquired 34 Partnership Shares in Haleon at a price of £3.71 per share and received an award of 34 Matching Shares at £0, giving an aggregated volume of 68 ordinary shares per person. The transactions took place on the London Stock Exchange and were reported in line with UK Market Abuse Regulation requirements.
Haleon plc reported its share count and voting rights as of 31 December 2025. The company had a total of 8,952,353,648 ordinary shares of £0.01 each in issue, of which 45,745,646 were held as treasury shares without voting rights.
After excluding treasury shares, the number of ordinary shares with voting rights was 8,906,608,002. Shareholders and others with disclosure obligations are asked to use this figure as the denominator when calculating whether they need to notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc announced changes to its board and committees. Alan Stewart will become Senior Independent Director when Vindi Banga is appointed Chair with effect from 1 January 2026. Stewart joined the board in September 2024 as a Non-Executive Director and Chair of the Audit & Risk Committee, and he will retain that position while also remaining on the Remuneration, Nominations & Governance and Environmental & Social Sustainability Committees.
In line with the UK Corporate Governance Code 2024, Vindi Banga will step down from the Audit & Risk Committee and the Remuneration Committee on 31 December 2025 and will become Chair of the Nominations & Governance Committee from 1 January 2026. Haleon confirmed that Banga’s remuneration as Chair will be £757,103 per annum, with further details to be included in the Company’s 2025 Annual Report & Accounts.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. On 9 December 2025, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 35 partnership shares in Haleon at a price of £3.57201 per ordinary share and received 35 matching shares at no cost. These ordinary shares have a nominal value of £0.01 each and are listed on the London Stock Exchange. The disclosure is made in line with UK Market Abuse Regulation requirements for transactions by persons discharging managerial responsibilities.
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.
These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.
Haleon plc reported its total voting rights and capital. As at 31 October 2025, the Company had 8,952,353,648 ordinary shares issued, including 45,930,962 held as treasury shares. After excluding treasury shares, the number of ordinary shares with voting rights is 8,906,422,686.
This voting-rights figure is the denominator shareholders and other obliged parties should use when assessing notification thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.
Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
